Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 250

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

IL-17 Signaling Accelerates the Progression of Nonalcoholic Fatty Liver Disease in Mice

Open access
Harley, Isaac T.W., Stankiewicz, Traci E., Giles, Daniel A., Softic, Samir, Flick, Leah M., Cappelletti, Monica, Sheridan, Rachel, Xanthakos, Stavra A., Steinbrecher, Kris A., Sartor, Balfour R., Kohli, Rohit, Karp, Christopher L., Divanovic, Senad · 2014 · Hepatology

Abstract

Inflammation plays a central pathogenic role in the pernicious metabolic and end-organ sequelae of obesity. Among these sequelae, nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in the developed world. The twinned observations that obesity is associated with increased activation of the interleukin (IL)-17 axis and that this axis can regulate liver damage in diverse contexts prompted us to address the role of IL-17RA signaling in the progression of NAFLD. We further examined whether microbe-driven IL-17A regulated NAFLD development and progression. We show here that IL-17RA−/− mice respond to high-fat diet stress with significantly greater weight gain, visceral adiposity, and hepatic steatosis than wild-type controls. However, obesity-driven lipid accumulation was uncoupled from its end-organ consequences in IL-17RA−/− mice, which exhibited decreased steatohepatitis, nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase enzyme expression, and hepatocellular damage. Neutralization of IL-17A significantly reduced obesity-driven hepatocellular damage in wild-type mice. Further, colonization of mice with segmented filamentous bacteria (SFB), a commensal that induces IL-17A production, exacerbated obesity-induced hepatocellular damage. In contrast, SFB depletion protected from obesity-induced hepatocellular damage. Conclusion : These data indicate that obesity-driven activation of the IL-17 axis is central to the development and progression of NAFLD to steatohepatitis and identify the IL-17 pathway as a novel therapeutic target in this condition. (Hepatology 2014;59:1830–1839)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.26746

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 250

Metadata

Authors
Harley, I. T. W., Stankiewicz, T. E., Giles, D. A., Softic, S., Flick, L. M., Cappelletti, M., Sheridan, R., Xanthakos, S. A., Steinbrecher, K. A., Sartor, B. R., Kohli, R., Karp, C. L., & Divanovic, S.
Venue
Hepatology
Published
2014-05
Volume
59
Issue
5
Pages
1830-1839
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2009868429
Cited by
250
References
14
FWCI
9.95
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IL-17 Signaling Accelerates the Progression of Nonalcoholic Fatty Liver Disease in Mice. https://app.cochat.ai/papers/10.1002/hep.26746
The paper
Harley, I. T. W., Stankiewicz, T. E., Giles, D. A., Softic, S., Flick, L. M., Cappelletti, M., Sheridan, R., Xanthakos, S. A., Steinbrecher, K. A., Sartor, B. R., Kohli, R., Karp, C. L., & Divanovic, S. (2014). IL-17 Signaling Accelerates the Progression of Nonalcoholic Fatty Liver Disease in Mice. Hepatology. https://doi.org/10.1002/hep.26746

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.